BRISTOL MYERS SQUIBB
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
Efficacy and Safety of BMS-690514 in Combination With Letrozole to Treat Metastatic Breast Cancer
- First Posted Date
- 2010-02-15
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 4
- Registration Number
- NCT01068704
- Locations
- 🇺🇸
Texas Oncology-Abilene, Abilene, Texas, United States
🇺🇸Texas Oncology-Beaumont, Beaumont, Texas, United States
🇺🇸Us Oncology Central Pharmacy, Fort Worth, Texas, United States
Drug Interaction Oral Contraceptive Pill (OCP)
- First Posted Date
- 2010-02-05
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 20
- Registration Number
- NCT01063023
- Locations
- 🇺🇸
Pra International, Lenexa, Kansas, United States
Efficacy and Safety Study of Entecavir Plus Tenofovir in Patients With Chronic Hepatitis B Who Failed Previous Treatment
- First Posted Date
- 2010-02-05
- Last Posted Date
- 2014-12-15
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 144
- Registration Number
- NCT01063036
- Locations
- 🇪🇸
Local Institution, Valencia, Spain
Safety Study of BMS-770767 in Subjects With Hypercholesterolemia
- First Posted Date
- 2010-01-28
- Last Posted Date
- 2012-04-19
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 81
- Registration Number
- NCT01058083
- Locations
- 🇺🇸
Cetero Research - San Antonio, San Antonio, Texas, United States
🇨🇦Local Institution, Montreal, Quebec, Canada
🇺🇸Harrell, Robert, Little Rock, Arkansas, United States
Multiple Dose Japanese Bridging Study
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2011-01-25
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 22
- Registration Number
- NCT01057030
- Locations
- 🇺🇸
California Clinical Trials Medical Group, Glendale, California, United States
Phase 3 Study of Immunotherapy to Treat Advanced Prostate Cancer
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 837
- Registration Number
- NCT01057810
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center At Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Baptist Cancer Institute, Jacksonville, Florida, United States
🇺🇸Md Anderson Cancer Center Orlando, Orlando, Florida, United States
An Anti-viral Combination Study With Japanese Hepatitis C Infection (HCV) Subject
- First Posted Date
- 2010-01-18
- Last Posted Date
- 2015-10-09
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 43
- Registration Number
- NCT01051414
- Locations
- 🇯🇵
Local Institution, Minato-Ku, Tokyo, Japan
Single Ascending Dose (BMS-813160) Study
- Conditions
- Accelerated Intimal Hyperplasia
- Interventions
- First Posted Date
- 2010-01-14
- Last Posted Date
- 2011-02-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 70
- Registration Number
- NCT01049165
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
Safety Study of BMS-770767 in Subjects With Type 2 Diabetes
- First Posted Date
- 2010-01-12
- Last Posted Date
- 2015-10-12
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 76
- Registration Number
- NCT01046422
- Locations
- 🇺🇸
Nevada Alliance Against Diabetes, Las Vegas, Nevada, United States
🇺🇸Marina Raikhel, Md, Lomita, California, United States
🇰🇷Local Institution, Suwon, Korea, Republic of
Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)
- Conditions
- Gastro-Intestinal Cancer
- Interventions
- First Posted Date
- 2010-01-12
- Last Posted Date
- 2014-09-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 49
- Registration Number
- NCT01046864
- Locations
- 🇺🇸
Scott & White Memorial Hospital And Clinic, Temple, Texas, United States
🇺🇸Texas Oncology, Dallas, Texas, United States
🇺🇸Usc/Norris Comprehensive Cancer Center, Los Angeles, California, United States